A study in the Journal of General Internal Medicine found initial monotherapy with metformin, instead of a sulfonylurea, was associated with a lower mortality risk for up to six years among veterans who developed type 2 diabetes, regardless of whether they had normal or mild to moderately impaired kidney function. The findings were based on data from the Veterans Health Administration for 175,296 patients.
Study links metformin to better survival in veterans with CKD
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.